Search

Your search keyword '"Del Giudice I"' showing total 114 results
Start Over Author "Del Giudice I" Search Limiters Full Text
114 results on '"Del Giudice I"'

1. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients

Author

Raponi, S., Del Giudice, I., Marinelli, M., Wang, J., Cafforio, L., Ilari, C., Piciocchi, A., Messina, M., Bonina, S., Tavolaro, S., Bordyuh, M., Mariglia, P., Peragine, N., Mauro, F.R., Chiaretti, S., Molica, S., Gentile, M., Visentin, A., Trentin, L., Rigolin, G.M., Cuneo, A., Diop, F., Rossi, D., Gaidano, G., Guarini, A., Rabadan, R., and Foà, R.

Published
2018
Full Text
View/download PDF

2. P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS

Author

Moia, R., primary, Favini, C., additional, Talotta, D., additional, Sagiraju, S., additional, Bruna, R., additional, Dondolin, R., additional, Della Starza, I., additional, Soscia, R., additional, Andorno, A., additional, Mercalli, F., additional, Deambrogi, C., additional, Rasi, S., additional, Petrucci, L., additional, Bellissimo, T., additional, Luciano Boldorini, R., additional, Di Rocco, A., additional, Del Giudice, I., additional, Martelli, M., additional, Foà, R., additional, and Gaidano, G., additional

Published
2022
Full Text
View/download PDF

3. P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY

Author

Natoni, A., primary, Cerreto, M., additional, De Propris, M. S., additional, Petrucci, M. T., additional, Del Giudice, I., additional, Intoppa, S., additional, Milani, M. L., additional, Kirkham-McCarthy, L., additional, Henderson, R., additional, Swan, D., additional, O’Dwyer, M., additional, Guarini, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

4. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript

Author

Fazio, F, Barberi, W, Cazzaniga, G, Fazio, G, Messina, M, Della Starza, I, De Propris, M, Mancini, F, Mohamed, S, Del Giudice, I, Chiaretti, S, Moleti, M, Guarini, A, Foa, R, Testi, A, Fazio F., Barberi W., Cazzaniga G., Fazio G., Messina M., Della Starza I., De Propris M. S., Mancini F., Mohamed S., Del Giudice I., Chiaretti S., Moleti M. L., Guarini A., Foa R., Testi A. M., Fazio, F, Barberi, W, Cazzaniga, G, Fazio, G, Messina, M, Della Starza, I, De Propris, M, Mancini, F, Mohamed, S, Del Giudice, I, Chiaretti, S, Moleti, M, Guarini, A, Foa, R, Testi, A, Fazio F., Barberi W., Cazzaniga G., Fazio G., Messina M., Della Starza I., De Propris M. S., Mancini F., Mohamed S., Del Giudice I., Chiaretti S., Moleti M. L., Guarini A., Foa R., and Testi A. M.

Published
2020

5. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Author

Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., Foa R., Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., and Foa R.

Abstract

NA

Published
2022

6. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

7. Does MRD have a role in the management of iNHL?

Author

Del Giudice, I., Starza, I. D., and Foa, R.

Subjects
Male, Neoplasm, Residual, Lymphoma, Non-Hodgkin, Disease Management, Indolent Lymphomas, indolent non-Hodgkin lymphomas, minimal residual disease, follicular lymphoma, Hematology, Middle Aged, Prognosis, Progression-Free Survival, Tumor Burden, body regions, hemic and lymphatic diseases, Humans, Female, Lymphoma, Follicular
Abstract

Among indolent non-Hodgkin lymphomas (iNHLs), the analysis of measurable/minimal residual disease (MRD) has been extensively applied to follicular lymphoma (FL). Treatment combinations have deeply changed over the years, as well as the techniques to measure MRD, which is currently evaluated only in the setting of clinical trials. Here, we discuss the evidence on the role of molecular monitoring in the management of FL. Mature data support the quantification of molecular tumor burden at diagnosis as a tool to stratify patients in risk categories and of MRD evaluation at the end of treatment to predict progression-free survival and overall survival. Moreover, MRD deserves further studies as a tool to refine the clinical/metabolic response and to modulate treatment intensity/duration. Patients with a higher relapse probability can be identified, but the relevance of continuous molecular follow-up should be clarified by kinetic models of MRD analysis. Being the BCL2/heavy chain immunoglobulin gene hybrid rearrangement detectable in about 50% to 60% of advanced FL and in 30% of positron emission tomography/computed tomography–staged localized FL, technical advancements such as next-generation sequencing/target locus amplification may allow broadening the FL population carrying a molecular marker. Droplet digital polymerase chain reaction can better quantify MRD at low levels, and novel sources of DNA, such as cell-free DNA, may represent a noninvasive tool to monitor MRD. Finally, MRD in other iNHLs, such as lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and marginal zone lymphoma, is beginning to be explored.

Published
2021

8. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Author

Morabito, F., Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, F. M., Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Cassin, R., D'Arrigo, G., Galimberti, S., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, P., Menichini, P., Olivieri, J., Cutrona, G., Rossi, D., Cuneo, A., Di Raimondo, F., Gaidano, G., Polliack, A., Trentin, L., Foa, R., Ferrarini, M., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., Gentile M., Morabito, F., Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, F. M., Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Cassin, R., D'Arrigo, G., Galimberti, S., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, P., Menichini, P., Olivieri, J., Cutrona, G., Rossi, D., Cuneo, A., Di Raimondo, F., Gaidano, G., Polliack, A., Trentin, L., Foa, R., Ferrarini, M., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., and Gentile M.

Abstract

n/a

Published
2021

9. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

Author

Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Mendicino, F., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, Paolo, Menichini, P., Cutrona, G., Jaksic, O., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., Gentile M., Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Mendicino, F., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, Paolo, Menichini, P., Cutrona, G., Jaksic, O., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., and Gentile M.

Abstract

Objectives: To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only. Methods: A real-life cohort of 675 cases has been identified and investigated in the database of the groups participating in the study. Results: At an unadjusted univariate analysis, a significant death risk reduction was observed favoring IB (IDELA-R vs IB HR = 0.5, 95% CI = 0.36-0.71) although with some limitations due to the non-randomized and retrospective nature of the study and to the lower number of patients in the IDELA-R group (112 cases) related to the current prescribing practice. To overcome the potential problem of confounding by indication, we adjusted the association between the type of therapy and mortality for all variables significantly associated with OS at Cox univariate analysis. Furthermore, those variables, differently distributed between the two study groups, were introduced into the multivariate Cox model to improve the effectiveness of the analysis. By introducing all these variables into the multiple Cox regression model, we confirmed the protective effect of IB vs IDELA-R (HR = 0.67, 95% CI = 0.45-0.98, P =.04) independent of potential confounders. Conclusions: Although our analysis presents some constraints, that is, the unavailability of additional potential confounders, and the retrospective nature of the study, this observation may be of help for the daily clinical practice, particularly in the absence of randomized trials comparing the two schedules.

Published
2021

10. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Author

Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Vigna, E., Martino, E. A., Mendicino, F., Botta, C., Caracciolo, D., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., Gentile M., Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Vigna, E., Martino, E. A., Mendicino, F., Botta, C., Caracciolo, D., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., and Gentile M.

Abstract

n/a

Published
2021

11. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Marino, Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Recchia, A. G., Varettoni, M., Murru, R., Chiarenza, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Fraticelli, V., Vigna, E., Botta, C., Tripepi, G., Arrigo, G. D., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Rigolin, G. M., Rossi, Dario, Di Raimondo, F., Gaidano, G., Polliack, A., Cuneo, A., Foa, Robin, Gattei, V., Gentile M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Rossi D., Foa R., Gentile, Marino, Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Recchia, A. G., Varettoni, M., Murru, R., Chiarenza, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Fraticelli, V., Vigna, E., Botta, C., Tripepi, G., Arrigo, G. D., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Rigolin, G. M., Rossi, Dario, Di Raimondo, F., Gaidano, G., Polliack, A., Cuneo, A., Foa, Robin, Gattei, V., Gentile M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Rossi D., and Foa R.

Abstract

N/A

Published
2021

15. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Author

Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Recchia, A. G., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Martino, E. A., Vigna, E., Tripepi, G., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Jaksic, O., Olivieri, J., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., Gentile M., Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Recchia, A. G., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Martino, E. A., Vigna, E., Tripepi, G., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Jaksic, O., Olivieri, J., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., and Gentile M.

Abstract

n/a

Published
2019

16. PF359 TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT

Author

Cafforio, L., primary, Cappelli, L.V., additional, Del Giudice, I., additional, Ilari, C., additional, Raponi, S., additional, De Propris, M.S., additional, Mariglia, P., additional, Mauro, F.R., additional, Piciocchi, A., additional, Giuliani, G., additional, Vignetti, M., additional, Guarini, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

17. PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Author

Mauro, F.R., primary, Molica, S., additional, Paoloni, F., additional, Reda, G., additional, Trentin, L., additional, Marchetti, M., additional, Pietrasanta, D., additional, Coscia, M., additional, Marasca, R., additional, Sportoletti, P., additional, Gaidano, G., additional, Orsucci, L., additional, Stelitano, C., additional, Di Renzo, N., additional, Liberati, A.M., additional, Gottardi, D., additional, Re, F., additional, Ilariucci, F., additional, Zinzani, P., additional, Mannina, D., additional, Gozzetti, A., additional, Molinari, A.L., additional, Gentile, M., additional, Consoli, U., additional, Laurenti, L., additional, Arcaini, L., additional, Ibatici, A., additional, Murru, R., additional, Tani, M., additional, De Propris, M.S., additional, Del Giudice, I., additional, Della Starza, I., additional, Raponi, S., additional, Nanni, M., additional, Fazi, P., additional, Crea, E., additional, Neri, A., additional, Specchia, G., additional, Guarini, A.R., additional, Cuneo, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

18. PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Author

Raponi, S., primary, Ilari, C., additional, Della Starza, I., additional, Del Giudice, I., additional, Cappelli, L.V., additional, Cafforio, L., additional, Piciocchi, A., additional, Bontempi, K., additional, Cavalli, M., additional, De Novi, L.A., additional, Mariglia, P., additional, Mauro, F.R., additional, Gentile, M., additional, Cutrona, G., additional, Moia, R., additional, Rossi, D., additional, Gaidano, G., additional, Morabito, F., additional, Guarini, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

19. Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

Author

Giovanni Manfredi Assanto ,, Matteo Totaro, Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, and Giuseppe Gentile

Subjects
B-cell malignancies, COVID-19, tixagevimab-cilgavimab, Pre-exposure prophylaxis, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), starting from asymptomatic disease to life threatening respiratory insufficiency. Onco-haematologic patients are at higher risk to develop severe COVID-19. In particular, patients affected by lymphoproliferative diseases, given the impaired cell-mediated and antibody-mediated immunity and treatment toxicity, develop more often a symptomatic and a more serious disease of Covid-19. Various therapeutic and prophylactic agents are being used against COVID‐19 such as antiviral drugs, vaccines and antiviral S‐protein monoclonal antibodies. Pre-exposure prophylaxis with AZD442/Evusheld (tixagevimab-cilgavimab) may be a complementary strategy to decrease the incidence or severity of COVID-19 for patients with B-cell malignancies. Tixagevimab-cilgavimab is a combination of two monoclonal antibodies that bind SARS-CoV-2 spike protein and inhibits the attachment to the surface of cells, preventing viral entry in the cell and COVID-19 development. In the setting of hematology real-life, few data are available on the impact of pre-exposure prophylaxis, given the multiple factors involved in the clinical behavior of SARS-CoV-2 . Our aim was to evaluate the clinical benefit and the safety of this strategy at our center.

Published
2023
Full Text
View/download PDF

20. Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia : Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Author

Del Giudice, I., Visentin, A., Trentin, L., Flogegard, M., Cavalloni, C., Orlandi, E., Mattsson, Mattias, Raponi, S., Ilari, C., Cafforio, L., De Propris, M. S., Della Starza, I., Peragine, N., Mariglia, P., Semenzato, G., Guarini, A., Montserrat, E., Foa, R., Del Giudice, I., Visentin, A., Trentin, L., Flogegard, M., Cavalloni, C., Orlandi, E., Mattsson, Mattias, Raponi, S., Ilari, C., Cafforio, L., De Propris, M. S., Della Starza, I., Peragine, N., Mariglia, P., Semenzato, G., Guarini, A., Montserrat, E., and Foa, R.

Published
2017

21. Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network

Author

Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, PICCALUGA P., on behalf of Fondazione Italiana Linfomi MrdNetwork, Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, PICCALUGA P., and on behalf of Fondazione Italiana Linfomi - MrdNetwork.

Subjects
Minimal Residual Disease, DNA extraction
Abstract

Genomic DNA extraction is a primary component of genomic research and diagnostic routine analysis. Recently, the importance of this process has been highlighted by the necessity to standardize the diagnostic procedure. In this regard, the Minimal Residual Disease (MRD) Network of the Fondazione Italiana Linfomi (FIL MRD Network) has performed a comparative study of four different commercially available kits for DNA extraction, applying them on a panel of cellular pellets, with the aim of defining possible technical recommendations in order to harmonize and standardize diagnostic procedures in the clinical setting. Overall, all four kits usually allowed the recovery of a significant quantity of high-quality DNA (in most conditions), although specific indications could be addressed for cellular pellets of different sizes.

Published
2014

22. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations

Author

Gian Matteo Rigolin, Del Giudice, I., Formigaro, L., Saccenti, E., Martinelli, S., Cavallari, M., Lista, E., Tammiso, E., Volta, E., Lupini, L., Bassi, C., Bardi, A., Sofritti, O., Daghia, G., Cavazzini, F., Marinelli, M., Tavolaro, S., Guarini, A., Negrini, M., Foa, R., and Cuneo, A.

Subjects
Adult, Male, Cancer Research, Oligonucleotides, Chromosome Disorders, leucemia linfatica cronica, NO, Time-to-Treatment, Cytogenetics, FISH, Genetics, Humans, Receptor, Notch1, In Situ Hybridization, Fluorescence, Aged, Aged, 80 and over, CLL, karyotype, Chromosomes, Human, Pair 13, Middle Aged, Ribonucleoprotein, U2 Small Nuclear, Phosphoproteins, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Recombinant Proteins, karyotype, citogenetica, FISH, prognosi, leucemia linfatica cronica, Karyotyping, Multivariate Analysis, Mutation, Interleukin-2, Female, RNA Splicing Factors, Chromosome Deletion, Mitogens, Tumor Suppressor Protein p53, Immunoglobulin Heavy Chains, citogenetica, prognosi, CLL, Chromosomes, Human, Pair 17
Abstract

To clarify whether karyotype aberrations (KA) involving regions not covered by the standard fluorescence in situ hybridization (FISH) panel have independent prognostic relevance, we evaluated KA by conventional cytogenetics in a learning cohort (LC; n = 166) and a validation cohort (VC; n = 250) of untreated chronic lymphocytic leukemia (CLL) patients. In the VC, novel mitogens were used to improve metaphase generation and TP53, NOTCH1, and SF3B1 mutations were assessed. KA undetected by FISH were found in 35 and 35% of the cases in the LC and VC, respectively. In addition to FISH, KA allowed reclassification of 23 and 26% of cases in the LC and VC, respectively, into a higher cytogenetic risk group. By multivariate analysis, both in the LC and VC, KA other than isolated 13q deletion correlated with a shorter time to first treatment (TFT; P0.001 and 0.003, respectively), while a complex karyotype predicted a worse overall survival (OS, P = 0.015 and 0.010, respectively). In the VC, where a comprehensive biologic assessment was performed, a shorter TFT was also predicted by stage (P0.001), IGHV mutational status (P = 0.05), and del(17p)/TP53 mutations (P = 0.033) while stage (P = 0.023) and del(17p)/TP53 mutations (P = 0.024) independently predicted a shorter OS. FISH results did not independently impact on TFT and OS, in the LC and VC cohorts; this was also the case for NOTCH1 and SF3B1 mutations in the VC. We suggest that in CLL, conventional karyotyping with novel mitogens could be more effective than FISH for the detection of KA allowing for a more precise refinement of prognosis.

Published
2015

23. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

Author

TESTI AM, DEL GIUDICE I, ARCESE W, MOLETI ML, GIONA F, BASSO G, BIONDI A, CONTER V, MESSINA C, RONDELLI R, MICOZZI A, MICALIZZI C, BARISONE E, LOCATELLI F, DINI G, ARICO M, COMIS M, LADOGANA S, LIPPI A, MURA R, PINTA MF, SANTORO N, VALSECCHI MG, MASERA G, MANDELLI F, AIEOP COOPERATIVE GROUP, CASALE, Fiorina, Testi, Am, DEL GIUDICE, I, Arcese, W, Moleti, Ml, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Arico, M, Casale, Fiorina, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, Mf, Santoro, N, Valsecchi, Mg, Masera, G, Mandelli, F, AIEOP COOPERATIVE, Group, Testi, A, Del Giudice, I, Moleti, M, Aricò, M, Casale, F, Pinta, M, and Valsecchi, M

Subjects
Male, Antineoplastic Combined Chemotherapy Protocol, Adolescent, Cytarabine, Hematopoietic Stem Cell Transplantation, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Disease-Free Survival, Follow-Up Studie, Survival Rate, Recurrence, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Preschool, Child, Idarubicin, Follow-Up Studies, Settore MED/15 - Malattie del Sangue, Human
Abstract

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complete remission; eight (8%) died during induction and 11 (11%) failed to respond. A total of 42 out of the 80 responders (52.5%) received a SCT: 19 from an identical sibling, 11 from a matched unrelated donor and 12 from umbilical cord blood cells. The estimated 4-year overall survival and event-free survival were 25% and 21% respectively. Disease-free survival at 4 years was 25.8% for the 80 responders. At 4 years, 39 out of 100 children remain alive, with 27 of them free of leukaemia. This induction therapy has shown antileukaemic efficacy with acceptable toxicity; moreover, all responders proved eligible for intensive consolidation.

Published
2002

24. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

Author

Foà, R, Del Giudice, I, Cuneo, Antonio, Del Poeta, G, Ciolli, S, Di Raimondo, F, Lauria, F, Cencini, E, Rigolin, Gian Matteo, Cortelezzi, A, Nobile, F, Callea, V, Brugiatelli, M, Massaia, M, Molica, S, Trentin, L, Rizzi, R, Specchia, G, Di Serio, F, Orsucci, L, Ambrosetti, A, Montillo, M, Luigi Zinzani, P, Ferrara, F, Morabito, F, Angela Mura, M, Soriani, S, Peragine, N, Tavolaro, S, Bonina, S, Marinelli, M, Stefania De Propris, M, Della Starza, I, Piciocchi, A, Alietti, A, Runggaldier, Ej, Gamba, E, Romana Mauro, F, Chiaretti, S, Guarini, A., R. Foà, I. D. Giudice, A. Cuneo, G. D. Poeta, S. Ciolli, F. D. Raimondo, F. Lauria, E. Cencini, G. M. Rigolin, A. Cortelezzi, F. Nobile, V. Callea, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, G. Specchia, F. D. Serio, L. Orsucci, A. Ambrosetti, M. Montillo, P. L. Zinzani, F. Ferrara, F. Morabito, M. A. Mura, S. Soriani, N. Peragine, S. Tavolaro, S. Bonina, M. Marinelli, M. S. De, I. D. Starza, A. Piciocchi, A. Alietti, E. J. Runggaldier, E. Gamba, F. R. Mauro, S. Chiaretti, and A. Guarini

Subjects
Male, Murine-Derived, drug therapy/pathology, Male, Survival Analysis, Treatment Outcome, Antibodies, Disease-Free Survival, Drug Administration Schedule, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, 80 and over, Antibodie, Humans, therapeutic use, Chlorambucil, Chronic, Aged, Aged, 80 and over, Aged, Aged, Leukemia, Chlorambucil, Female, Induction Chemotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab, Survival Analysis, Treatment Outcome, Hematology, B-Cell, Lymphocytic, CLL, chlorambucil, administration /&/ dosage, Antineoplastic Combined Chemotherapy Protocol, administration /&/ dosage, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Induction Chemotherapy, Leukemia, Settore MED/15 - Malattie del Sangue
Abstract

In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m(2) ; cycles 4-8, 500 mg/m(2) ). Responders were randomized to 12 8-week doses of R (375 mg/m(2) ) or observation. As per intention-to-treat analysis, 82.4\% (95\% CI, 74.25-90.46\%) of 85 patients achieved an overall response (OR), 16.5\% a complete response (CR), 2.4\% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4\%, B 81.6\%, and C 78.6\%) and age categories (60-64 years, 92.3\%; 65-69, 85.2\%; 70-74, 75.0\%; ≥75, 81.0\%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95\% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patients.

Published
2014

25. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Author

Rossi, D, Terzi-di-Bergamo, L, De Paoli, Luigi, Cerri, Marco Vittorio, Ghilardi, Giampaolo, Chiarenza, A, Bulian, P, Visco, C, Mauro, Fr, Morabito, F, Cortelezzi, A, Zaja, F, Forconi, F, Laurenti, Luca, Del Giudice, I, Gentile, M, Vincelli, I, Motta, M, Coscia, M, Rigolin, Gm, Tedeschi, Alessandra, Neri, A, Marasca, R, Perbellini, O, Moreno, C, Del Poeta, G, Massaia, M, Zinzani, Pl, Montillo, M, Cuneo, A, Gattei, V, Foà, R, Gaidano, G, Laurenti L (ORCID:0000-0002-8327-1396), Rossi, D, Terzi-di-Bergamo, L, De Paoli, Luigi, Cerri, Marco Vittorio, Ghilardi, Giampaolo, Chiarenza, A, Bulian, P, Visco, C, Mauro, Fr, Morabito, F, Cortelezzi, A, Zaja, F, Forconi, F, Laurenti, Luca, Del Giudice, I, Gentile, M, Vincelli, I, Motta, M, Coscia, M, Rigolin, Gm, Tedeschi, Alessandra, Neri, A, Marasca, R, Perbellini, O, Moreno, C, Del Poeta, G, Massaia, M, Zinzani, Pl, Montillo, M, Cuneo, A, Gattei, V, Foà, R, Gaidano, G, and Laurenti L (ORCID:0000-0002-8327-1396)

Abstract

X

Published
2015

26. IGHV1-69/D3-16/J3 subset 6 is associate with indolent disease course of early stage CLL (RAI 0) independent of unmutated status

Author

Forconi, F., Cencini, E., Rossi, D., Sozzi, E., Bomben, R., Marasca, R., Coscia, Marta, Massaia, Massimo, Veronese, S., Tedeschi, A., Montillo, M., Fazzi, R., Petrini, M., Ciolli, S., Bosi, A., Dottori, R., Pirrotta, M., Caremani, A., Del Poeta, G., Del Giudice, I., Santangelo, S., Laurenti, L., Efremov, D., Trentin, L., Bertoni, F., Gattei, V., Gaidano, G., and Lauria, F.

Published
2010

27. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Author

Mauro, Fr, Molica, S, Laurenti, Luca, Cortelezzi, A, Carella, Am, Zaja, F, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, M, Starza, Id, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A, Foà, R., Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Fr, Molica, S, Laurenti, Luca, Cortelezzi, A, Carella, Am, Zaja, F, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, M, Starza, Id, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A, Foà, R., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Published
2014

28. Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Author

Mauro, F. R., Cortelezzi, A., Molica, S., Laurenti, L., Liso, V., Rizzi, R., Carella, A. M., DI RAIMONDO, Francesco, Marasca, R., Fioritoni, G., Brugiatelli, M., Musolino, C., Lauria, F., Buccisano, F., Zaja, F., Callea, V., Morabito, F., Massaia, M., Gentile, G., DEL GIUDICE, I., DE PROPRIS, M. S., DELLA STARZA, I., Marinelli, M., Santangelo, S., Nanni, M., Vignetti, M., Graziosi, A., Specchia, G., Cuneo, A., Guarini, A., Blood, AND R. FOÀ ., and Vol, P.

Published
2008

31. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

Author

Del Giudice, I, Rossi, D, Chiaretti, S, Marinelli, M, Tavolaro, S, Gabrielli, S, Laurenti, Luca, Marasca, R, Rasi, S, Fangazio, M, Guarini, A, Gaidano, G, Foà, R., Laurenti, Luca (ORCID:0000-0002-8327-1396), Del Giudice, I, Rossi, D, Chiaretti, S, Marinelli, M, Tavolaro, S, Gabrielli, S, Laurenti, Luca, Marasca, R, Rasi, S, Fangazio, M, Guarini, A, Gaidano, G, Foà, R., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

Trisomy 12, the third most frequent chromosomal aberration in chronic lymphocytic leukemia (CLL), confers an intermediate prognosis. In our cohort of 104 untreated patients carrying +12, NOTCH1 mutations occurred in 24% of cases and were associated to unmutated IGHV genes (P=0.003) and +12 as a sole cytogenetic abnormality (P=0.008). NOTCH1 mutations in +12 CLL associated with an approximately 2.4 fold increase in the risk of death, a significant shortening of survival (P<0.01) and proved to be an independent predictor of survival in multivariate analysis. Analogous to +12 CLL with TP53 disruption or del(11q), NOTCH1 mutations in +12 CLL conferred a significantly worse survival compared to that of +12 CLL with del(13q) or +12 only. The overrepresentation of cell cycle/proliferation related genes of +12 CLL with NOTCH1 mutations suggests the biological contribution of NOTCH1 mutations to determine a poor outcome. NOTCH1 mutations refine the intermediate prognosis of +12 CLL.

Published
2012

32. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage

Author

Dal Bo, M, Del Giudice, I, Bomben, R, Capello, D, Bertoni, Francesco, Forconi, F, Laurenti, Luca, Rossi, Dario, Zucchetto, A, Pozzato, G, Marasca, R, Efremov, Dg, Guarini, A, Del Poeta, G, Foà, R, Gaidano, G, Gattei, V., Laurenti, Luca (ORCID:0000-0002-8327-1396), Dal Bo, M, Del Giudice, I, Bomben, R, Capello, D, Bertoni, Francesco, Forconi, F, Laurenti, Luca, Rossi, Dario, Zucchetto, A, Pozzato, G, Marasca, R, Efremov, Dg, Guarini, A, Del Poeta, G, Foà, R, Gaidano, G, Gattei, V., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement.

Published
2011

33. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia

Author

Dal Bo, M, Rossi, D, Deambrogi, C, Bertoni, Francesco, Del Giudice, I, Palumbo, Giuseppe, Nanni, Marinella, Rinaldi, A, Kwee, I, Tissino, E, Corradini, Gaia, Gozzetti, Alessandra, Cencini, E, Ladetto, M, Coletta, Am, Luciano, F, Bulian, P, Pozzato, G, Laurenti, Luca, Forconi, F, Di Raimondo, F, Marasca, R, Del Poeta, G, Gaidano, G, Foà, R, Guarini, A, Gattei, V., Laurenti, Luca (ORCID:0000-0002-8327-1396), Dal Bo, M, Rossi, D, Deambrogi, C, Bertoni, Francesco, Del Giudice, I, Palumbo, Giuseppe, Nanni, Marinella, Rinaldi, A, Kwee, I, Tissino, E, Corradini, Gaia, Gozzetti, Alessandra, Cencini, E, Ladetto, M, Coletta, Am, Luciano, F, Bulian, P, Pozzato, G, Laurenti, Luca, Forconi, F, Di Raimondo, F, Marasca, R, Del Poeta, G, Gaidano, G, Foà, R, Guarini, A, Gattei, V., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

Deletion at 13q14 is detected by fluorescence in situ hybridization (FISH) in about 50% of chronic lymphocytic leukemia (CLL). Although CLL with 13q deletion as the sole cytogenetic abnormality (del13q-only) usually have good prognosis, more aggressive clinical courses are documented for del13q-only CLL carrying higher percentages of 13q deleted nuclei. Moreover, deletion at 13q of different sizes have been described, whose prognostic significance is still unknown. In a multi-institutional cohort of 342 del13q-only cases and in a consecutive unselected cohort of 265 CLL, we investigated the prognostic significance of 13q deletion, using the 13q FISH probes locus-specific identifier (LSI)-D13S319 and LSI-RB1 that detect the DLEU2/MIR15A/MIR16-1 and RB1 loci, respectively. Results indicated that both percentage of deleted nuclei and presence of larger deletions involving the RB1 locus cooperated to refine the prognosis of del13q-only cases. In particular, CLL carrying <70% of 13q deleted nuclei with deletions not comprising the RB1 locus were characterized by particularly long time-to-treatment. Conversely, CLL with 13q deletion in <70% of nuclei but involving the RB1 locus, or CLL carrying 13q deletion in ≥70% of nuclei, with or without RB1 deletions, collectively experienced shorter time-to-treatment. A revised flowchart for the prognostic FISH assessment of del13q-only CLL, implying the usage of both 13q probes, is proposed.

Published
2011

35. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

Author

Del Giudice, I., primary, Rossi, D., additional, Chiaretti, S., additional, Marinelli, M., additional, Tavolaro, S., additional, Gabrielli, S., additional, Laurenti, L., additional, Marasca, R., additional, Rasi, S., additional, Fangazio, M., additional, Guarini, A., additional, Gaidano, G., additional, and Foa, R., additional

Published
2011
Full Text
View/download PDF

36. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

Author

Guarini, A., primary, Marinelli, M., additional, Tavolaro, S., additional, Bellacchio, E., additional, Magliozzi, M., additional, Chiaretti, S., additional, De Propris, M. S., additional, Peragine, N., additional, Santangelo, S., additional, Paoloni, F., additional, Nanni, M., additional, Del Giudice, I., additional, Mauro, F. R., additional, Torrente, I., additional, and Foa, R., additional

Published
2011
Full Text
View/download PDF

37. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia

Author

Del Giudice, I., primary, Mauro, F. R., additional, De Propris, M. S., additional, Santangelo, S., additional, Marinelli, M., additional, Peragine, N., additional, Di Maio, V., additional, Nanni, M., additional, Barzotti, R., additional, Mancini, F., additional, Armiento, D., additional, Paoloni, F., additional, Guarini, A., additional, and Foa, R., additional

Published
2010
Full Text
View/download PDF

38. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

Author

Testi, A, Del Giudice, I, Arcese, W, Moleti, M, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Aricò, M, Casale, F, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, M, Santoro, N, Valsecchi, M, Masera, G, Mandelli, F, Testi, AM, Moleti, ML, BIONDI, ANDREA, Pinta, MF, Mandelli, F., VALSECCHI, MARIA GRAZIA, Testi, A, Del Giudice, I, Arcese, W, Moleti, M, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Aricò, M, Casale, F, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, M, Santoro, N, Valsecchi, M, Masera, G, Mandelli, F, Testi, AM, Moleti, ML, BIONDI, ANDREA, Pinta, MF, Mandelli, F., and VALSECCHI, MARIA GRAZIA

Abstract

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complete remission; eight (8%) died during induction and 11 (11%) failed to respond. A total of 42 out of the 80 responders (52.5%) received a SCT: 19 from an identical sibling, 11 from a matched unrelated donor and 12 from umbilical cord blood cells. The estimated 4-year overall survival and event-free survival were 25% and 21% respectively. Disease-free survival at 4 years was 25.8% for the 80 responders. At 4 years, 39 out of 100 children remain alive, with 27 of them free of leukaemia. This induction therapy has shown antileukaemic efficacy with acceptable toxicity; moreover, all responders proved eligible for intensive consolidation

Published
2002

39. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with Acute Lymphoblastic Leukemia. Experience at the University 'La Sapienza' of Rome

Author

Testi, A. M., Moleti, M. L., Giona, F., Annino, L., Sabina CHIARETTI, Del Giudice, I., Todisco, E., D Elia, G., Ferrari, A., Arcese, W., and Mandelli, F.

Subjects
relapse, Adult, Male, Antibiotics, Antineoplastic, Adolescent, Dose-Response Relationship, Drug, Universities, Rome, Cytarabine, Infant, acute lymphoblastic leukemia, chemotherapy, cytosine arabinoside, idarubicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hospitals, University, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Child, Idarubicin
Abstract

The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL). In an attempt to minimize the non-hematologic toxicity and obtain a potent antileukemic effect, MSKCC activated a pilot study in previously treated adult ALL, using HD-ARA-C combined with idarubicin administered as a single high-dose infusion. We herein report our experience with a series of pediatric and adult high risk ALL and NHL patients treated with the protocol above, which confirms its feasibility, response rate and individual compliance.In a clinical phase II study, the combination of a single high dose (HD) of idarubicin and HD cytosine-arabinoside (ARA-C), as designed at the Memorial Sloan Kettering Cancer Center, was applied to 70 adults and children with refractory or early relapse acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic non-Hodgkin's lymphoma (NHL). Therapy consisted of HD-ARA-C 3 g/m2/d on days 1-5, idarubicin 40 mg/m2 on day 3, prophylactic intrathecal methotrexate on days 1 and 4, and G-CSF 5 mg/kg/d s.c. from day 7 to hematopoietic reconstitution (PMN0.5 x 10(9)/L).Fifty-five of the 70 patients (78%) achieved complete remission (CR), four died in aplasia due to infection and 11 were non-responders. Recovery of blood counts occurred at a median of 21 days from the start of treatment. Non-hematologic side effects were extremely limited and consisted predominantly of infections.In view of the highly unfavorable series of patients selected, this study confirms the feasibility and antileukemic activity of the HD-idarubicin + HD-ARA-C combination in patients with refractory and early relapse ALL and NHL. The excellent tolerance to this regimen does not preclude bone marrow transplantation as post-remission treatment.

41. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Silvia Bolis, Ilaria Del Giudice, Donato Mannina, Stefano Luminari, Jacopo Olivieri, Annalisa Arcari, Luigi Marcheselli, Simone Ferrero, Martina Manni, Francesca Ricci, S. Kovalchuk, Tetiana Skrypets, Caterina Stelitano, Anna Merli, Antonella Anastasia, Alessandra Tucci, Lucia Farina, Massimo Federico, M. Ladetto, Stephane Chauvie, Annalisa Chiarenza, Carola Boccomini, Luca Guerra, Fondazione Italiana Linfomi, Vincenzo Pavone, Annibale Versari, Federica Cavallo, Vittorio Ruggero Zilioli, Antonello Pinto, Caterina Patti, Alessandra Dondi, Sara Galimberti, Gloria Margiotta Casaluci, Luca Arcaini, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, and Federico, M

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Lymphoma, PET/CT, Follicular lymphoma, MEDLINE, follicular lymphoma, minimal residual disease, treatment, Text mining, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, Prospective Studies, Cyclophosphamide, Doxorubicin, Female, Follow-Up Studies, Induction Chemotherapy, Lymphoma, Follicular, Middle Aged, Prednisone, Prognosis, Rituximab, Survival Rate, Vincristine, business.industry, Advanced stage, Follicular, medicine.disease, PET, business, medicine.drug
Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naïve, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n = 65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively ( P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRD-negative.

Published
2022

42. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Valter Gattei, Gian Matteo Rigolin, Yair Herishanu, Aaron Polliack, Annalisa Chiarenza, Francesca Rossi, Fortunato Morabito, Marzia Varettoni, Paolo Sportoletti, Roberta Murru, Riccardo Bomben, Gianluigi Reda, Giovanni Tripepi, Giacomo Loseto, Luca Laurenti, Graziella D’. Arrigo, Annalisa Biagi, Antonella Zucchetto, Adalgisa Condoluci, Ugo Consoli, Antonio Cuneo, Ilaria Del Giudice, Davide Rossi, Anna Grazia Recchia, Francesco Di Raimondo, Riccardo Moia, Giovanni Del Poeta, Robin Foà, Gianluca Gaidano, Ilaria Scortechini, Vincenzo Fraticelli, Ilaria Angeletti, Daniela Pietrasanta, Angela Rago, Cirino Botta, Marta Coscia, Ernesto Vigna, Francesca Romana Mauro, Massimo Gentile, Gentile M., Morabito F., Del Poeta G., Mauro F.R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Recchia A.G., Varettoni M., Murru R., Chiarenza A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Rossi F.M., Zucchetto A., Fraticelli V., Vigna E., Botta C., Tripepi G., Arrigo G.D., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Rigolin G.M., Rossi D., Di Raimondo F., Gaidano G., Polliack A., Cuneo A., Foa R., and Gattei V.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Survival risk score, Chronic lymphocytic leukemia, Treatment outcome, Antineoplastic Agents, risk score, NO, chemistry.chemical_compound, relapsed/refractory chronic lymphocytic leukemia, Antineoplastic Agents, Immunological, Piperidines, ibrutinib, Internal medicine, medicine, Humans, real-life, Molecular Targeted Therapy, Chronic, Protein Kinase Inhibitors, Framingham Risk Score, Leukemia, chronic lymphocytic leukemia, prognosis, business.industry, Adenine, B-Cell, Hematology, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, prognostic score, Lymphocytic, Survival risk score, real-life, relapsed/refractory chronic lymphocytic leukemia, ibrutinib, Settore MED/15 - MALATTIE DEL SANGUE, Immunological, Treatment Outcome, chemistry, Ibrutinib, Relapsed refractory, business
Published
2021

43. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Author

Ilaria Scortechini, Riccardo Moia, Marzia Varettoni, Francesca Romana Mauro, Sara Galimberti, Giovanni Del Poeta, Graziella D'Arrigo, Marta Coscia, Luca Laurenti, Ernesto Vigna, Davide Rossi, Annalisa Biagi, Gianluca Gaidano, Daniele Caracciolo, Riccardo Bomben, Ilaria Angeletti, Gianluigi Reda, Giovanna Cutrona, Daniela Pietrasanta, Gilberto Fronza, Ramona Cassin, Antonino Neri, Aaron Polliack, Annalisa Chiarenza, Yair Herishanu, Fortunato Morabito, Ilaria Del Giudice, Valter Gattei, Francesca Rossi, Roberta Murru, Giovanni Tripepi, Andrea Visentin, Livio Trentin, Antonio Cuneo, Angela Rago, Antonella Zucchetto, Adalgisa Condoluci, Giacomo Loseto, Ugo Consoli, Enrica Antonia Martino, Manlio Ferrarini, Massimo Gentile, Francesco Di Raimondo, Francesco Mendicino, Paolo Sportoletti, Robin Foà, Cirino Botta, Morabito F., Tripepi G., Del Poeta G., Mauro F.R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Varettoni M., Murru R., Chiarenza A., Visentin A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Rossi F.M., Zucchetto A., Vigna E., Martino E.A., Mendicino F., Botta C., Caracciolo D., Cassin R., D'Arrigo G., Galimberti S., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Neri A., Fronza G., Cutrona G., Rossi D., Di Raimondo F., Cuneo A., Gaidano G., Polliack A., Trentin L., Foa R., Ferrarini M., Gattei V., and Gentile M.

Subjects
Oncology, Male, chronic B cell leukemia, chronic lymphocytic leukemia, ibrutinib, 4-factor score, prognosis, Datasets as Topic, Severity of Illness Index, chemistry.chemical_compound, Piperidines, Retrospective analysis, Multicenter Studies as Topic, Chronic, Leukemia, Hematology, Middle Aged, Prognosis, Lymphocytic, Progression-Free Survival, Ibrutinib, Female, medicine.medical_specialty, real-word study, Factor score, Antineoplastic Agents, Adenine, Aged, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Proportional Hazards Models, Protein Kinase Inhibitors, Reproducibility of Results, Retrospective Studies, Risk Assessment, Survival Analysis, NO, Internal medicine, Severity of illness, medicine, Progression-free survival, Survival analysis, business.industry, Proportional hazards model, B-Cell, Retrospective cohort study, Settore MED/15 - MALATTIE DEL SANGUE, chemistry, business, chronic lymphocytic leukaemia
Abstract

Not Available

Published
2021

44. High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

Author

Caterina Musolino, Francesco Albano, Emanuele Angelucci, Francesca Romana Mauro, Fiorella Ilariucci, Alessandra Tedeschi, Sara Raponi, Roberta Battistini, Antonio Cuneo, Francesco Zaja, Stefano Soddu, Gianluigi Reda, Alessandro Gozzetti, Alfonso Piciocchi, Marta Coscia, Antonino Neri, Francesca Re, Anna Marina Liberati, Daniela Pietrasanta, Mauro Nanni, Anna Guarini, Maria Stefania De Propris, Robin Foà, Irene Della Starza, Ilaria Del Giudice, Stefano Molica, Marco Vignetti, Giovanni Del Poeta, Mauro, Fr, Molica, S, Soddu, S, Ilariucci, F, Coscia, M, Zaja, F, Angelucci, E, Re, F, Liberati, Am, Tedeschi, A, Reda, G, Pietrasanta, D, Gozzetti, A, Battistini, R, Del Poeta, G, Musolino, C, Nanni, M, Piciocchi, A, Vignetti, M, Neri, A, Albano, F, Cuneo, A, Del Giudice, I, Della Starza, I, De Propris, M, Raponi, S, Guarini, Ar, and Foà, R.

Subjects
Oncology, medicine.medical_specialty, Cyclophosphamide, Chronic lymphocytic leukemia, Lymphoproliferative disorders, Ofatumumab, Antibodies, Monoclonal, Humanized, NO, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Chronic Lymphocytic Leukemia, Letters to the Editor, Minimal Residual Disease, Lymphoproliferative Disorders, business.industry, Front line, Hematology, medicine.disease, Settore MED/15, Minimal residual disease, Leukemia, Lymphocytic, Chronic, B-Cell, Fludarabine, Treatment Outcome, chemistry, N/A, Chronic Lymphocytic Leukemia, Lymphoproliferative Disorders, IGHV@, business, Rituximab, Vidarabine, medicine.drug
Abstract

N/A

Published
2020

45. Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network

Author

Barbara Mantoan, Elisa Genuardi, Martina Ferrante, Irene Della Starza, Elena Ciabatti, Susanna Grassi, Lucia Anna De Novi, Marzia Cavalli, Claudia Mannu, Anna Gazzola, Riccardo Bomben, Massimo Degan, Beatrice Alessandria, Christiane Pott, Marie-Hélène Delfau-Larue, Ramon García-Sanz, Claudio Agostinelli, Valter Gattei, Sara Galimberti, Ilaria Del Giudice, Gianluca Gaidano, Marco Ladetto, Simone Ferrero, Daniela Drandi, on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network, Mantoan B., Genuardi E., Ferrante M., Starza I.D., Ciabatti E., Grassi S., de Novi L.A., Cavalli M., Mannu C., Gazzola A., Bomben R., Degan M., Alessandria B., Pott C., Delfau-Larue M.-H., Garcia-Sanz R., Agostinelli C., Gattei V., Galimberti S., Del Giudice I., Gaidano G., Ladetto M., Ferrero S., and Drandi D.

Subjects
Oncology, medicine.medical_specialty, Letter, Standardization, Quality assessment, business.industry, Hematology, medicine.disease, Minimal residual disease, Lymphoma, MRD, lymphoma, Internal medicine, Medicine, Diseases of the blood and blood-forming organs, RC633-647.5, business
Abstract

No abstract available

Published
2021

46. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

Author

Francesca Romana Mauro, Sruthi Sagiraju, Davide Rossi, Giovanni Del Poeta, Denise Peroni, Silvia Rasi, Ken I. Mills, Gian Matteo Rigolin, Sarah Lawless, Riccardo Bomben, Ilaria Del Giudice, Annalisa Chiarenza, Robin Foà, Francesca Arruga, Fary Diop, Alessio Bruscaggin, Marina Motta, Luca Laurenti, Marta Coscia, Ramesh Adhinaveni, Lorenzo De Paoli, Patrick Thornton, Phil Weir, Chiara Favini, Simone Favini, Riccardo Moia, Roberto Marasca, Carlo Visco, Antonio Cuneo, Omar Perbellini, Antonia Follenzi, Lodovico Terzi-di-Bergamo, Francesca Rossi, Renzo Boldorini, Andrea Patriarca, Alessandra Tedeschi, Clara Deambrogi, Ahad Ahmed Kodipad, Elisa Spaccarotella, Mark Catherwood, Chiara Tarantelli, Clive Jabangwe, Valeria Spina, Francesco Forconi, Francesco Bertoni, Francesco Zaja, David Donaldson, Valter Gattei, Gianluca Gaidano, Agostino Cortelezzi, Silvia Deaglio, Diop, F., Moia, R., Favini, C., Spaccarotella, E., De Paoli, L., Bruscaggin, A., Spina, V., Terzi-Di-Bergamo, L., Arruga, F., Tarantelli, C., Deambrogi, C., Rasi, S., Adhinaveni, R., Patriarca, A., Favini, S., Sagiraju, S., Jabangwe, C., Kodipad, A. A., Peroni, D., Mauro, F. R., Del Giudice, I., Forconi, F., Cortelezzi, A., Zaja, F., Bomben, R., Rossi, F. M., Visco, C., Chiarenza, A., Rigolin, G. M., Marasca, R., Coscia, M., Perbellini, O., Tedeschi, A., Laurenti, L., Motta, M., Donaldson, D., Weir, P., Mills, K., Thornton, P., Lawless, S., Bertoni, F., Poeta, G. D., Cuneo, A., Follenzi, A., Gattei, V., Boldorini, R. L., Catherwood, M., Deaglio, S., Foa, R., Gaidano, G., and Rossi, D.

Subjects
Oncology, medicine.medical_specialty, Cyclophosphamide, Chronic lymphocytic leukemia, chronic lymphocytic leukemia, BIRC-3, prognosis, medicine.disease_cause, Chronic Lymphocytic Leukemia, Cytogenetics and Molecular Genetics, Molecular predictors, Article, NO, 03 medical and health sciences, 0302 clinical medicine, Chemoimmunotherapy, Internal medicine, medicine, Univariate analysis, Mutation, BIRC3 CLL prognosis, business.industry, Hematology, medicine.disease, Settore MED/15, 3. Good health, Fludarabine, Leukemia, Settore MED/15 - MALATTIE DEL SANGUE, Birc3, IGHV@, business, 030215 immunology, medicine.drug
Abstract

BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting analysis, we showed that the non-canonical nuclear factor-κB pathway is active in BIRC3-mutated cell lines and in primary CLL samples, as documented by the stabilization of MAP3K14 and by the nuclear localization of p52. In addition, BIRC3-mutated primary CLL cells are less sensitive to flu-darabine. In order to confirm in patients that BIRC3 mutations confer resistance to fludarabine-based chemoimmunotherapy, a retrospective multicenter cohort of 287 untreated patients receiving first-line FCR was analyzed by targeted next-generation sequencing of 24 recurrently mutated genes in CLL. By univariate analysis adjusted for multiple comparisons BIRC3 mutations identify a poor prognostic subgroup of patients in whom FCR treatment fails (median progression-free survival: 2.2 years, P

Published
2019

47. Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis

Author

Irene Dogliotti, Manuela Gambella, Marzia Cavalli, Claudio Agostinelli, Elena Ciabatti, I. Del Giudice, Claudia Mannu, I. Della Starza, Pier Paolo Piccaluga, Elisa Genuardi, Daniela Barbero, Simone Ferrero, Anna Gazzola, S Grassi, Luigia Monitillo, Gian Maria Zaccaria, L.A. De Novi, Marco Ladetto, Daniela Drandi, Barbara Mantoan, S Galimberti, Genuardi, E., Barbero, D., Dogliotti, I., Mantoan, B., Drandi, D., Gambella, M., Zaccaria, G.M., Monitillo, L., Della Starza, I., Cavalli, M., De Novi, L.A., Ciabatti, E., Grassi, S., Gazzola, A., Mannu, C., Del Giudice, I., Galimberti, S., Agostinelli, C., Piccaluga, P.P., Ladetto, M., and Ferrero, S.

Subjects
medicine.medical_specialty, Neoplasm, Residual, cell recovering, Mononuclear, Clinical Biochemistry, Follicular lymphoma, Ficoll, Urology, Diatrizoate, Peripheral blood mononuclear cell, Hemolysis, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, red blood cell lysis, Leukocytes, Methods, Humans, Whole blood, Clinical Trials as Topic, Hematology, business.industry, Biochemistry (medical), General Medicine, medicine.disease, Minimal residual disease, medicine.anatomical_structure, minimal residual disease, Residual, 030220 oncology & carcinogenesis, Leukocytes, Mononuclear, Neoplasm, Mantle cell lymphoma, Bone marrow, business, red blood cell lysi, 030215 immunology
Abstract

Introduction The high-throughput era remarkably changed molecular laboratory practice. Actually, the increasing number of processed samples requires to reduce the risk of operator biases, by automating or simplifying as much as possible both the analytical and the pre-analytical phases. Minimal residual disease (MRD) studies in hematology often require a simultaneous processing of many bone marrow and peripheral blood samples from patients enrolled in prospective, multicenter, clinical trials, monitored at several planned time points. Methods In this study, we demonstrate that red blood cell lysis (RBL) pre-analytical procedure can replace the time-consuming Ficoll stratification as cell recovering step. Here, we show a MRD comparison study using both total white blood cells and mononuclear cells recovered by the 2 procedures from 46 follicular lymphoma (FL), 15 multiple myeloma (MM), and 11 mantle cell lymphoma (MCL) patients enrolled in prospective clinical trials. Results The experiments were performed in the 4 laboratories of the Fondazione Italiana Linfomi (FIL) MRD Network and showed superimposable results, in terms of good correlation (R = 0.87) of the MRD data obtained by recovering blood cells by the 2 approaches. Conclusion Based on these results, the FIL MRD Network suggests to optimize the pre-analytical phases introducing RBL approach for cell recovery in the clinical trials including MRD analysis.

Published
2017

48. Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain react

Author

Robin Foà, Claudia Mannu, Irene Della Starza, Ilaria Del Giudice, Elisa Genuardi, Gianluca Gaidano, Anna Gazzola, Marzia Cavalli, Daniela Barbero, Sara Galimberti, Luigia Monitillo, Marco Ladetto, Elena Ciabatti, Pier Paolo Piccaluga, Anna Guarini, Barbara Mantoan, Marina Urbano, Della Starza I, Cavalli M, Del Giudice I, Barbero D, Mantoan B, Genuardi E, Urbano M, Mannu C, Gazzola A, Ciabatti E, Guarini A, Foà R, Galimberti S, PICCALUGA P., Gaidano G, Ladetto M, and Monitillo L

Subjects
Lymphoproliferative disorders, Immunoglobulin gene, Cancer Research, Neoplasm, Residual, MRD, RQ-PCR, lymphoproliferative disorders, immunoglobulin genes, mutations, MINIMAL RESIDUAL DISEASE, Biology, Real-Time Polymerase Chain Reaction, medicine.disease_cause, Immunoglobulin genes, Mutations, Gene Frequency, Gene Rearrangement, Humans, Immunoglobulin Heavy Chains, Lymphoproliferative Disorders, Genes, Immunoglobulin, Mutation, Oncology, Hematology, LYMPHOMA, Immunoglobulin, medicine, Genetics, General Medicine, Gene rearrangement, medicine.disease, Minimal residual disease, Molecular biology, Real-Time PCR (qPCR), Real-time polymerase chain reaction, Genes, Residual, Neoplasm, Immunoglobulin heavy chain, Primer (molecular biology)
Abstract

We compared two strategies for minimal residual disease evaluation of B-cell lymphoproliferative disorders characterized by a variable immunoglobulin heavy chain (IGH) genes mutation load. Twenty-five samples from chronic lymphocytic leukaemia (n = 18) or mantle cell lymphoma (n = 7) patients were analyzed. Based on IGH variable region genes, 22/25 samples carried >2% mutations, 20/25 > 5%. In the IGH joining region genes, 23/25 samples carried >2% mutations, 18/25 > 5%. Real-time quantitative polymerase chain reaction was performed on IGH genes using two strategies: method A utilizes two patient-specific primers, whereas method B employs one patient-specific and one germline primer, with different positions on the variable, diversity and joining regions. Twenty-three samples (92%) resulted evaluable using method A, only six (24%) by method B. Method B poor performance was specifically evident among mutated IGH variable/joining region cases, although no specific mutation load above, which the real-time quantitative polymerase chain reaction failed was found. The molecular strategies for minimal residual disease evaluation should be adapted to the B-cell receptor features of the disease investigated. Copyright © 2013 John Wiley & Sons, Ltd.

Published
2013

49. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial

Author

Marzia Cavalli, Francesca Guerrini, Barbara Mantoan, Alessandra Dondi, Giuseppe A. Palumbo, Gianluca Gaidano, Luca Arcaini, Luigia Monitillo, Pier Paolo Piccaluga, Mario Petrini, Luigi Rigacci, Claudia Mannu, Irene Della Starza, Ilaria Del Giudice, Anna Gazzola, Alessandra Tucci, Stefano Luminari, Massimo Federico, Daniele Vallisa, Susanna Grassi, Sara Galimberti, Pellegrino Musto, Luigi Marcheselli, Elena Ciabatti, Umberto Vitolo, Carola Boccomini, Marco Ladetto, Giovanni Bertoldero, Alessandro Pulsoni, Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, PICCALUGA P., Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, and Federico M.

Subjects
Male, Cancer Research, Neoplasm, Residual, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase III as Topic, Female, Gene Dosage, Gene Rearrangement, Genes, bcl-2, Humans, Immunoglobulin Heavy Chains, Lymphoma, Follicular, Middle Aged, Prognosis, ROC Curve, Real-Time Polymerase Chain Reaction, Treatment Outcome, Young Adult, Oncology, Lymphoma, bcl-2, Follicular lymphoma, Gastroenterology, hemic and lymphatic diseases, Phase III as Topic, medicine.anatomical_structure, Residual, medicine.medical_specialty, MRD, FOLL05, Chemoimmunotherapy, Internal medicine, medicine, Follicular lymphoma, MRD, Clinical Trials, Progression-free survival, business.industry, Follicular, Cancer, Gene rearrangement, medicine.disease, Minimal residual disease, Surgery, Genes, Neoplasm, Bone marrow, business
Abstract

Purpose: The role of the minimal residual disease (MRD) in follicular lymphoma is still debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a prognostic role in patients receiving R-CHOP, R-FM, or R-CVP. Experimental Design: DNAs from 415 patients among the 504 cases enrolled in the FOLL05 trial (NCT00774826) were centralized and assessed for the BCL2/IGH at diagnosis, at the end of treatment, and after 12 and 24 months. Results: At diagnosis, the molecular marker was detected in 53% of cases. Patients without molecular marker or with a low molecular tumor burden ( Conclusions: In this study, standardized molecular techniques have been adopted and applied on bone marrow samples from a large cohort. Data reported show that the MRD detection is a powerful independent predictor of PFS in patients with follicular lymphoma receiving conventional chemoimmunotherapy. Clin Cancer Res; 20(24); 6398–405. ©2014 AACR.

Published
2014

50. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Author

Mauro Francesca, R, Molica, Stefano, Laurenti, Luca, Cortelezzi, Agostino, Carella Angelo, M., Zaja, Francesco, Chiarenza, Annalisa, Angrilli, Francesco, Nobile, Francesco, Marasca, Roberto, Musolino, Caterina, Brugiatelli, Maura, Piciocchi, Alfonso, Vignetti, Marco, Fazi, Paola, Gentile, Giuseppe, De Propris Maria, S., Starza Irene Della, Marinelli, Marilisa, Chiaretti, Sabina, Del Giudice Ilaria, Nanni, Mauro, Albano, Francesco, Cuneo, Antonio, Guarini, Anna, Foà, Robin, per il gruppo GIMEMA Working Party Chronic Lymph, Massaia, M., Mauro, Fr, Molica, S, Laurenti, L, Cortelezzi, A, Carella, Am, Zaja, Francesco, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, M, Della Starza, I, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A, and Foà, R.

Subjects
Oncology, Male, Cancer Research, medicine.medical_treatment, Chronic lymphocytic leukemia, THERAPY, Fludarabine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Chronic, Alemtuzumab, Humanized, Vidarabine, Neoadjuvant therapy, Hematology, Leukemia, STEM CELL TRANSPLANTATION, Medicine (all), Middle Aged, Lymphocytic, Neoadjuvant Therapy, Treatment Outcome, Female, PHASE-II TRIAL, medicine.drug, EXPRESSION, Adult, medicine.medical_specialty, Young, Biology, CLL, Antibodies, Monoclonal, Humanized, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, Antibodies, Chronic lymphocytic leukemia, CLL, Young, Biology, Fludarabine, Alemtuzumab, STEM CELL TRANSPLANTATION, PHASE-II TRIAL, TERM FOLLOW UP, SUBCUTANEOUS ALEMTUZUMAB, DISEASE PROGRESSION, POOR PROGNOSIS, FREE SURVIVAL, EXPRESSION, RITUXIMAB, THERAPY, Internal medicine, SUBCUTANEOUS ALEMTUZUMAB, RITUXIMAB, Survival analysis, business.industry, DISEASE PROGRESSION, B-Cell, medicine.disease, Transplantation, Settore MED/15 - MALATTIE DEL SANGUE, POOR PROGNOSIS, Immunology, TERM FOLLOW UP, FREE SURVIVAL, business
Abstract

In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results